多参数磁共振成像检测个体前列腺癌病灶的准确性研究
该回顾性研究分析了588例经活检证实前列腺癌患者根治术前的3-T mpMRI与全 mount 病理对照,共1213个病理确认病灶。mpMRI对全部病灶的检出率为45%,对临床显著病灶为65%,近80%高级别肿瘤被检出。34%患者至少一个临床显著病灶被遗漏,多灶患者中达45%。
要点
- mpMRI对前列腺癌个体病灶的检出率不足一半(45%),临床显著病灶为65%。
- 小、低级别、多灶、非指数肿瘤及PSA密度较低者更易被遗漏。
- 34%患者至少一个临床显著病灶被遗漏,多灶患者中达45%。
核心结论
- mpMRI检测不到一半的全部前列腺癌病灶和不到三分之二的临床显著病灶。
- 中等程度的每病灶敏感性和相当比例患者存在未检出病灶,说明mpMRI目前存在局限。
研究设计与样本
- 回顾性分析前瞻性管理数据库,将mpMRI病灶特异性结果与根治性前列腺切除标本的全mount病理进行配准。
- 纳入2010年6月至2018年2月单中心连续588例活检证实前列腺癌、根治术前接受3-T mpMRI的患者。
- 最终分析纳入588例患者中1213个病理确认肿瘤病灶,主要为中危(75%)或高危(12%)前列腺癌。
主要发现
- mpMRI检出全部病灶的45%(95%CI 42-47%),临床显著病灶的65%(95%CI 61-69%),近80%高级别肿瘤。
- 遗漏的孤立性和多灶性肿瘤中分别有74%和31%为临床显著。
- 遗漏病灶大多数较小(61.1%≤1cm),28.3%在1-2cm之间,10.4%>2cm。
- mpMRI在34%患者中至少遗漏一个临床显著病灶,在多灶病变患者中达45%。
- 多因素分析显示,较小、低级别、多灶、非指数肿瘤及PSA密度较低者更易被遗漏。
临床怎么用
- 临床应认识到mpMRI对个体前列腺癌病灶检出的中等敏感性,尤其对小、低级别、多灶及PSA密度低的病灶。
- 在制定管理策略时需考虑mpMRI可能遗漏相当比例的临床显著病灶,尤其多灶患者。
局限性
- 选择偏倚:队列为接受前列腺切除术的患者。
- 缺乏特异性数据。
- 图像与病理配准过程不完美。
- 未检出病灶的临床意义不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiparametric magnetic resonance imaging (mpMRI) undoubtedly affects the diagnosis and treatment of localized prostate cancer (CaP). However, clinicians need a better understanding of its accuracy and limitations in detecting individual CaP foci to optimize management. OBJECTIVE: To determine the per-lesion detection rate for CaP foci by mpMRI and identify predictors of tumor detection. DESIGN, SETTING, AND PARTICIPANTS: We carried out a retrospective analysis of a prospectively managed database correlating lesion-specific results from mpMRI co-registered with whole-mount pathology (WMP) prostatectomy specimens from June 2010 to February 2018. Participants include 588 consecutive patients with biopsy-proven CaP undergoing 3-T mpMRI before radical prostatectomy at a single tertiary institution. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured mpMRI sensitivity in detecting individual CaP and clinically significant (any Gleason score ≥7) CaP foci and predictors of tumor detection using multivariate analysis. RESULTS AND LIMITATIONS: The final analysis included 1213 pathologically confirmed tumor foci in 588 patients with primarily intermediate- (75%) or high-risk (12%) CaP. mpMRI detected 45% of all lesions (95% confidence interval [CI] 42-47%), including 65% of clinically significant lesions (95% CI 61-69%) and nearly 80% of high-grade tumors. Some 74% and 31% of missed solitary and multifocal tumors, respectively, were clinically significant. The majority of missed lesions were small (61.1% ≤1cm); 28.3% were between 1 and 2cm, and 10.4% were >2cm. mpMRI missed at least one clinically significant focus in 34% of patients overall, and in 45% of men with multifocal lesions. On multivariate analysis, smaller, low-grade, multifocal, nonindex tumors with lower prostate-specific antigen density were more likely to be missed. Limitations include selection bias in a prostatectomy cohort, lack of specificity data, an imperfect co-registration process, and uncertain clinical significance for undetected lesions. CONCLUSIONS: mpMRI detects less than half of all and less than two-thirds of clinically significant CaP foci. The moderate per-lesion sensitivity and significant proportion of men with undetected tumor foci demonstrate the current limitations of mpMRI. PATIENT SUMMARY: Magnetic resonance imaging of the prostate before surgical removal for prostate cancer finds less than half of all individual prostate cancer tumors. Large, solitary, aggressive tumors are more likely to be visualized on imaging.
引用
- Johnson DC, Raman SS, Mirak SA, et al. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. Eur Urol. 2018. PMID: 30509763. doi:10.1016/j.eururo.2018.11.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。